In addition, neovascular retinal disease such as AMD and DME are the most common indications of use for intravitreal anti-VEGF drugs, and are characterised by retinal neurodegeneration (de Jong, 2006; Tian et al., 2007) Indeed, AMD and DME share common biological pathways with neurodegenerative processes, such as oxidative stress and inflammation. The gene discussed is VEGFA; the disease is age-related macular degeneration.